Melt Pharmaceuticals Stock
Melt Pharmaceuticals develops non-opioid, needle-free sedation and analgesia products for use in outpatient procedures. Its lead product candidate is a sublingual formulation intended to replace IV sedation for short medical interventions, aiming to improve patient experience and reduce recovery times.
For more Melt Pharmaceuticals stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Larry Dillaha, M.D. Chief Executive Officer |
| Brad Osborne Chief Financial Officer |
